Packaging Corporation of America News
UPS, Molson Make Goldman's List of Dividend Stocks
Dividend stocks can offer safety in a volatile market. Both Goldman and Bank of America favor them now.
General Electric, Celgene, Dollar Tree: 'Mad Money' Lightning Round
Jim Cramer takes a closer look at General Electric, Celgene, Dollar Tree, STMicroelectronics, Chico's, Campbell Soup, Copart, Yext and more.
Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap
Jim Cramer says the market like this economy; he has your game plan for next week.
Analysts' Actions -- Danaher, Twilio, Under Armour, UPS and More
Here are Wednesday's top research calls, including upgrades for Danaher and Twilio, and downgrades for Under Armour and United Parcel Service.
Earnings, Not Politics, Are Still Driving This Market: Cramer's 'Mad Money' Recap (Friday 1/27/17)
Jim Cramer talks about how to position your portfolio for maximum returns in this earnings season.
Analysts' Actions -- Alcoa, CenturyLink, JetBlue, Verizon and More
Here are Wednesday's top research calls, including upgrades for Alcoa, CenturyLink and JetBlue, and a pair of downgrades for Verizon.
Analysts' Actions -- Anthem, Fortinet, Harley-Davidson, Viacom and More
Here are Tuesday's top research calls, including upgrades for Anthem, Fortinet and Harley-Davidson, and a downgrade for Viacom.
Analysts' Actions -- Costco, Intel, Prudential, Yahoo! and More
Here are Tuesday's top research calls, including an upgrade for Intel, downgrades for Prudential and Yahoo!, and new coverage of Costco.
Analysts' Actions -- Electronic Arts, Prudential, Twitter, Yum Brands and More
Here are Friday's top research calls, including an upgrade for Prudential, downgrades for Twitter and Yum Brands, and new coverage of Electronic Arts.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.